Questex Expands Life Sciences Portfolio with Acquisitions of The Conference Forum and Versalinx Global Events
Questex has announced the acquisition of The Conference Forum and Versalinx Global Events, strengthening its position in the rapidly growing $88.2 billion life sciences industry. The move expands Questex’s Fierce Healthcare & Life Sciences portfolio and aligns with the company’s broader strategy of growth through both organic development and targeted acquisitions.
Expanding Reach in Life Sciences and Healthcare
The life sciences sector, valued at $88.2 billion in 2024, is projected to grow to $269.56 billion by 2034, according to Towards Healthcare. Questex’s acquisition of The Conference Forum and Versalinx Global Events is designed to broaden its global reach, enhance its event offerings, and provide customers greater access to professional networks and new markets.
“The two newly acquired companies significantly expand Questex’s Healthcare & Life Sciences portfolio and position us to meet rising market demand,” said Paul Miller, CEO of Questex. “Both organizations share our focus on connecting buyers and sellers through formats that foster learning, networking, and business growth. We’re confident these investments will create meaningful expansion opportunities.”
About The Conference Forum
The Conference Forum organizes research-driven events that connect stakeholders across the life sciences ecosystem, including buyers, sellers, patients, and investors. The company’s six conferences—such as DPHARM and Partnership Opportunities in Drug Delivery (PODD)—focus on areas like clinical trials, immuno-oncology, patient engagement, and drug delivery.
Five of these events expand Questex’s footprint into new biopharma segments, further integrating the company across the life sciences value chain. The Conference Forum also brings a database of 100,000 qualified pharma professionals, complementing Questex’s existing audience of 1.5 million healthcare and life sciences professionals.
Co-founders Valerie Bowling and Meredith Sands, along with their teams, will join Questex as part of the integration.
About Versalinx Global Events
Versalinx Global Events specializes in conferences focused on pharmaceutical market research and competitive intelligence. The company hosts five events in the United States and Europe, including its flagship Pharma Market Research Conference East.
Founder Amy Yueh and her team will also join Questex following the acquisition.
Integration into the Fierce Healthcare & Life Sciences Platform
The newly acquired assets will become part of Questex’s Fierce Healthcare & Life Sciences platform under the leadership of Rhiannon James, Group President of Healthcare & Life Sciences, Technology, and Wellness.
“Fierce has become a powerhouse across the life sciences and healthcare ecosystem—driving innovation, insight, and connection,” James said. “By adding The Conference Forum and Versalinx Global Events, we’re expanding our reach, deepening our impact, and accelerating growth across the life sciences value chain.”
Continuing Strategic Expansion
This acquisition follows Questex’s recent moves in adjacent markets, including the purchase of the event and media assets of Affordable Housing Finance and Multifamily Executive, reflecting the company’s broader effort to expand its event and media footprint across high-growth industries.
